Clinical value of ezrin expression in primary osteosarcoma.

Cancer Res Treat 2009 Sep 28;41(3):138-44. Epub 2009 Sep 28.

Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.

Purpose: Ezrin is a membrane cytoskeletal linker protein and it is known to be associated with metastasis of primary osteosarcoma. The aim of this study is to determine the relationship between an ezrin expression and several key clinical parameters and to elucidate its potential prognostic value for patients with osteosarcoma.

Materials And Methods: Seventy patients with histologically confirmed osteosarcoma and who had no distant metastasis were enrolled between 1995 and 2005 at Yonsei Cancer Center, Severance Hospital, Korea. The clinical parameters were retrospectively reviewed and immunohistochemical staining (IHC) for ezrin was performed using the surgically resected specimens.

Results: Of the 70 tumor specimens, 39 (55.7%) revealed an ezrin expression. More of an osteoblastic histology and an elevated initial ALP level were observed in the ezrin positive patients than in the ezrin negative patients (p=0.008 and 0.001, respectively). The proportion of patients who favorably responded to neoadjuvant chemotherapy (≥or=90% necrosis) was significantly higher in the group of ezrin positive patients than that in the group of ezrin negative patient (72.2% vs 45.2%, respectively, p=0.024). The ezrin positive patients showed more frequent recurrence than did the ezrin negative patients (64.1% vs 35.5%, respectively, p=0.017). The patients with an ezrin expression also demonstrated poorer survival than did those patients without ezrin expression (5-year EFS: 31.7% vs 61.3%, respectively, p=0.023, 5-year OS: 53.4% vs 71.0%, respectively, p=0.022). When comparing EFS according to both an ezrin expression and chemoresponsiveness, there were trends that the ezrin negative/chemoresponsive group showed the best 5-year EFS (71.4%), followed by the ezrin negative/chemoresistant group (52.9%), the ezrin positive/chemoresponsive group (38.1%) and the ezrin positive/chemoresistant group (13.6%). These trends were statistically significant (p=0.036).

Conclusion: The expression of ezrin by IHC staining was found in 55.7% of the patients with metastasis-free osteosarcoma. Immunoreactivity to ezrin is a negative prognostic factor for survival for the patients suffering with osteosarcoma. Identifying an ezrin expression might offer a valuable piece of information when treating patients with primary osteosarcoma.

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2009.41.3.138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757658PMC
September 2009
27 Reads

Publication Analysis

Top Keywords

ezrin expression
28
ezrin
20
ezrin negative
16
patients
13
patients ezrin
12
positive patients
12
ezrin positive
12
primary osteosarcoma
12
clinical parameters
8
group ezrin
8
survival patients
8
expression
8
negative patients
8
5-year efs
8
group
6
osteosarcoma
6
5-year 534%
4
frequent recurrence
4
recurrence ezrin
4
patients frequent
4

Altmetric Statistics

References

(Supplied by CrossRef)

Meyers et al.
J Clin Oncol 1992

Bacci et al.
Cancer 2006

Kalifa et al.
Cancer Treat Res 1993

Clark et al.
J Cancer Res Clin Oncol 2008

Bretscher et al.
Nat Rev Mol Cell Biol 2002

Hunter et al.
Trends Mol Med 2004

Elliott et al.
Breast Cancer Res 2005

Weng et al.
Clin Cancer Res 2005

Elzagheid et al.
Hum Pathol 2008

Moilanen et al.
Gynecol Oncol 2003

Khanna et al.
Nat Med 2004

Similar Publications